MPM BioImpact
Crossover fundBoston · Pre-Seed–Series C · 32 people tracked
Investment thesis
MPM BioImpact invests in biopharmaceutical companies across all development phases that aim to transform patient outcomes and lives. The firm leverages its entrepreneur partner network to provide deep domain expertise spanning the entire drug development process and regulatory navigation. The investment approach integrates impact considerations with traditional venture capital and public market strategies.
Source: firm website, verified Jul 21, 2026.
Team · 32 people
from the firm's websiteManaging Partner and founder of MPM Capital in 1992 as a biotech venture capital firm. Led investments in major successes including BioMarin Pharmaceuticals, Pharmasset (acquired by Gilead), and Cullinan Therapeutics. Recipient of 2017 Global Oncology Visionary Award.
Managing Partner leading the firm's public market investing as portfolio manager for BioImpact Equities and Oncology Impact Funds. Previously served as a healthcare analyst at Fidelity Investments covering biotechnology, life-science tools and diagnostics. Holds M.D. from Harvard Medical School and M.B.A. from Harvard Business School.
Managing Director and serial entrepreneur with deep expertise in oncology and immuno-oncology. Recently served as CEO of portfolio company NextPoint Therapeutics and currently chairs its Board. Previously President and CEO of Surface Oncology and held strategic roles at AstraZeneca and Novartis.
Managing Director who joined the firm in 1999. Serves as Chairman of multiple portfolio company boards and has guided significant M&A outcomes including Semma Therapeutics acquisition by Vertex for $950M and Selexys acquisition by Novartis for $665M.
Executive Partner with over 25 years of financial leadership experience in venture capital, managing Investment Committees and portfolio construction. Previously served as Chief Operating Officer and Chief Financial Officer. Held senior finance roles at Atlas Venture, Flare Capital Partners, and Softbank Capital.
Partner responsible for investment identification and due diligence of public equities. Spent majority of career in drug discovery for precision oncology and immunotherapy, most recently as Senior Director of Cancer Biology at Scorpion Therapeutics. Ph.D. from MIT in Genetics.
Head of APAC region focusing exclusively on early-stage investment and company creation opportunities. Previously spent 16 years at Temasek, most recently as Director of Life Sciences Investment, investing in healthcare companies including Juno Therapeutics and Guardant Health.
Principal responsible for investment identification, due diligence, and company creation in the APAC region. Previously spent five years at Hillhouse Capital covering global healthcare investments. Ph.D. research focused on amyloid fibrils in Parkinson's disease using cryo-electron microscopy.
Principal responsible for driving investments and company creation activities. Previously Principal at Flagship Pioneering where he co-founded Senda Biosciences and Montai Health. Completed postdoctoral fellowship at the Wyss Institute for Biologically Inspired Engineering at Harvard.
Principal focused on early-stage investments and company creation activities. Previously spent seven years at 8VC where he co-led the life sciences practice, co-founding several companies and serving on multiple boards. Ph.D. research focused on statistical and machine learning approaches for genomics data.
Principal focusing on private investments and new company formation. Previously Principal at Apple Tree Partners where he contributed to starting eight biotech companies. Founding scientist at Jnana Therapeutics and member of biotech equity research team at Citigroup.
Entrepreneur Partner and founder/CEO of portfolio company Umoja Biopharma. Previously Attending Physician at Seattle Children's Hospital and Professor in Department of Pediatrics at University of Washington School of Medicine. Chief Scientific Officer at Cellectis Therapeutics and co-founder of Pregenen Inc.
Entrepreneur Partner and co-founder/CEO of Reversing Early Recurrence. Serves as Director of the Massachusetts General Hospital Global Cancer Care Program and Co-Director of GI Cancer Program. Associate Professor of Medicine at Harvard Medical School and gastrointestinal oncologist.
Chief Compliance Officer of the firm. Previously served as Senior Principal Consultant at ACA Group supporting venture capital and private equity funds in developing compliance programs. Licensed attorney with the Commonwealth of Massachusetts.
Entrepreneur Partner serving on the board of NextPoint Therapeutics. Previously Chief Business Officer at Orna Therapeutics and ReNAgade Therapeutics. Senior Vice President of Corporate Development at Bristol Myers Squibb and Vice President of Business Development at Johnson & Johnson.
Entrepreneur Partner and CEO of portfolio company Crossbow Therapeutics. Served as Chief Medical Officer and Executive Vice President for Global Medicines Development at AstraZeneca with experience overseeing clinical development at Pfizer and Merck.
Chairperson of the Medical and Scientific Advisory Board. Anne T. and Robert M. Bass Professor of Chemistry at Stanford University and Howard Hughes Medical Institute Investigator. 2022 Nobel Prize laureate in Chemistry for founding the field of bioorthogonal chemistry. Founded 12 biotechnology companies through her academic research.
Head of Fund Investor Relations and Strategic Finance leading fundraising and investor engagement initiatives. Previously Senior Director at Flagship Pioneering focusing on capital formation across life sciences venture creation funds and investor relations head at Moderna.
Director of Investor Relations responsible for coordinating existing and prospective investor relations efforts. Previously worked at Turbonomic, a Boston-based technology firm, and raised capital for privately held companies.
Chief Financial Officer overseeing the firm's finance functions. Brings 20+ years of CFO experience at alternative investment firms including Lincoln Peak Capital and HighVista Strategies. Previously Manager of Investment and Treasury Operations at Williams College.
Entrepreneur Partner serving as Senior Clinical Advisor to Rhythm Pharmaceuticals. Brings decades of international biopharma industry experience including interim CEO of Semma Therapeutics and founding CMO/CDO of Rhythm. Previously Senior Vice President of Global Clinical Development Operations at Merck.
Entrepreneur Partner and Acting Chief Medical Officer of portfolio company K2 Therapeutics. Brings extensive experience in cell therapy and oncology clinical development. Previously Senior Vice President and Global Head of Clinical Development at Kite, a Gilead Company.
Vice President of Legal at the firm. Previously worked at 5AM Ventures and Moderna advising on complex licensing transactions and strategic M&A. Began legal career at Kirkland & Ellis LLP focusing on private equity and public company M&A.
IP Counsel serving several portfolio companies. Previously IP strategy architect for venture-backed life sciences companies and Vice President, IP at Flagship Ventures. Practiced patent counseling at national law firms Mintz Levin, Proskauer Rose, and Foley Hoag.
Co-founder of the predecessor company MPM Capital in 1997 and Advisor to the firm. Served as interim CEO of publicly traded Werewolf Therapeutics and co-founded seven MPM portfolio companies including Blade Therapeutics, Harpoon Therapeutics, and Tizona Therapeutics over a 30+ year venture capital career.
Entrepreneur Partner and CEO of portfolio company Aktis Oncology. Previously held senior leadership roles at Bristol Myers Squibb as Senior Vice President and Head of Enterprise Strategy. Earlier served as Head of Biotechnology Equity Research at UBS Investment Bank.
Entrepreneur Partner and CEO of portfolio company Ashibio. Brings over two decades of drug development experience including roles at Gilead Sciences as Vice President and Head of Oncology Therapeutic Area, and previously served as Chief Medical Officer at Dicerna Pharmaceuticals.
General Counsel of the firm. Previously spent 35 years at Sullivan and Cromwell LLP as a trusted advisor on novel and complex transactions including capital markets, M&A, joint ventures, and corporate restructuring. J.D. from Yale Law School.
Senior Associate responsible for investment identification and due diligence of public equities. Previously a fellow with the firm surveilling scientific fields. Completed Ph.D. in Computational and Systems Biology at MIT focusing on AI/ML methodologies for analyzing molecular data.
What they invest in
from 16 of 26 portfolio companiesBiotech ×16Medical Devices ×13Digital Health ×5Healthtech ×5AI & Machine Learning ×3Deep Tech ×1FemTech ×1Mental Health ×1
HQs:United States×6
Investments · 26 tracked
founders shown can be your intro pathTransforming the radiopharmaceutical field to deliver significant patient impact potential.
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors. The company serves oncology patients and healthcare providers in the cancer care sector.
BiotechHealthtechMedical Devices
Todd Foley(Co-founder and Chairman)Patrick Baeuerle(Co-founder & Advisor)
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry. The company targets an unmet clinical need where no approved therapeutic options currently exist.
BiotechFemTechHealthtechMedical Devices
Developing Vyvgart, a successful drug therapy addressing shared underlying pathology across multiple autoimmune diseases.
Arialys Therapeutics develops precision medicines targeting pathogenic autoantibodies in the brain to treat neuropsychiatric disorders driven by autoimmune disease. The company focuses on blocking autoantibodies that target brain receptors like NMDA receptors, with initial applications in conditions including encephalitis, schizophrenia, and dementia.
BiotechDigital HealthMedical Devices
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies. The company creates next-generation T-cell engagers incorporating its proprietary T-Bolt™ molecules to enhance therapeutic potency and manufacturability.
AI & Machine LearningBiotechMedical Devices
Cullinan Therapeutics develops clinical-stage T cell engager therapies targeting autoimmune diseases and cancer, leveraging immune modulation expertise to advance high-impact therapeutic candidates.
BiotechDigital Health
Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform. The company focuses on discovery, clinical development, and commercialization of treatments for rare genetic disorders.
BiotechMedical DevicesWaltham, US
ElevateBio is a contract development and manufacturing organization (CDMO) that provides end-to-end services for cell and gene therapies, from discovery and process development through clinical and commercial-scale manufacturing.
BiotechDeep TechMedical Devices
Mike Paglia(Chief Technology Officer)
Entrada Therapeutics develops intracellular therapeutics using its EEV Platform to target previously inaccessible disease-causing targets within cells, with a pipeline spanning retinal, neuromuscular, and metabolic diseases including Duchenne muscular dystrophy.
BiotechHealthtechMedical DevicesBoston, US
Fable Therapeutics develops biologics for metabolic disease treatment, specifically targeting the ActR2 pathway to address obesity and related comorbidities through protein engineering. The company is advancing a pipeline of therapeutic candidates designed to reduce body weight and fat while preserving muscle and improving metabolic health.
BiotechHealthtechMedical Devices
Frontier Meds develops small-molecule drugs targeting previously undruggable protein targets using a proprietary approach to identify and exploit novel binding sites across the human proteome.
Biotech
NextPoint is developing precision cancer therapeutics based on the B7-H7/HHLA2 axis, including T-cell engagers, antibody-drug conjugates, and checkpoint inhibitors for cancer patients. The company focuses on immuno-oncology and tumor-targeting therapies.
BiotechDigital HealthMedical DevicesAustin, US
Orna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications. The company leverages proprietary drug development expertise in oRNA and LNP technology platforms.
AI & Machine LearningBiotechMedical Devices
Joe Bolen(Chief Executive Officer)Joe Bolen, Ph.D.(Chief Executive Officer)Hope D'Oyley-Gay, JD(Chief Legal Officer)Ciaran Lawlor, Ph.D.(Chief Operating Officer)
Pioneering a new treatment paradigm for severe mental health disorders with rapid-acting and well-tolerated therapeutic options.
Reunion develops serotonergic psychedelic therapies for mental health conditions, targeting postpartum depression, adjustment disorder, and generalized anxiety disorder. The company is advancing luvesilocin, a clinical-stage drug candidate and patented prodrug designed to provide fast-acting antidepressive effects.
BiotechDigital HealthMental Health
Sahil V. Kirpekar(President and CEO)
Umoja Biopharma develops in vivo CAR T cell therapies for cancer treatment using its VivoVec platform, which generates CAR T cells directly in patients' bodies. The company operates its own manufacturing facility to produce these cancer immunotherapies.
BiotechDigital HealthMedical Devices
Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer. The company focuses on leveraging immune modulation and innovative therapeutic approaches in oncology.
BiotechHealthtechMedical DevicesWatertown, US
Daniel J. Hicklin(Founder, President, Chief Executive Officer, and Board member)Luke Evnin(Co-founder, Board member (Chairman))
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs. The company is focused on rare genetic conditions including cystic fibrosis and primary ciliary dyskinesia.
AI & Machine LearningBiotechMedical Devices
Dr. Daniel J. Siegwart
Board seats · per SEC filings · 2
what is this? ⓘ$175M raise · filed Oct 2024 · via Todd Foley
Raise · filed Dec 2020 · via Todd Foley
Inferred from directors named on each company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does MPM BioImpact invest at?
- MPM BioImpact invests at the Pre-Seed, Seed, Series A, Series B, Series C stages.
- What sectors does MPM BioImpact focus on?
- MPM BioImpact focuses on Biotech, Impact & Social Good.
- Where is MPM BioImpact located?
- MPM BioImpact is headquartered in Boston, US.
Similar investors
Innovestor is a Finnish investment manager that operates across venture capital, real estate, and energy storage sectors. The firm invests in early-stage technology and life science startups, energy-efficient commercial real estate, and battery storage and solar solutions. Innovestor also provides corporate venturing advisory services.
Octopus Ventures is a pan-European early-stage venture capital firm that invests from pre-seed through Series A and beyond, with pre-seed investments typically at £100k and later-stage investments starting at £1 million.
Novo Holdings is a holding and investment company managing the assets of the Novo Nordisk Foundation, one of the world's largest enterprise foundations. The firm invests in life science companies across all development stages and manages a diversified portfolio including equities, bonds, real estate, infrastructure, and private equity.
Forbion is a global venture capital firm focused on advancing biotech innovations and sustainable solutions that improve human and planetary health. The firm operates across three offices in the Netherlands, Germany, and the United States.
B Capital is a venture capital firm managing $12+ billion in assets under management with 200+ early to late-stage portfolio companies across 9 global locations. The firm operates dedicated stage-based funds supporting entrepreneurs throughout the company-building lifecycle.